Isn't it ironic? Cost-effectiveness and willingness to pay for tolvaptan in the prevention of kidney failure in autosomal dominant polycystic kidney disease

Robert Nee, Christina M. Yuan, Kevin C. Abbott*

*Corresponding author for this work

Research output: Contribution to journalEditorial

3 Scopus citations
Original languageEnglish
Pages (from-to)552-554
Number of pages3
JournalAmerican Journal of Kidney Diseases
Volume63
Issue number4
DOIs
StatePublished - Apr 2014
Externally publishedYes

Fingerprint

Dive into the research topics of 'Isn't it ironic? Cost-effectiveness and willingness to pay for tolvaptan in the prevention of kidney failure in autosomal dominant polycystic kidney disease'. Together they form a unique fingerprint.

Cite this